Profit and Loss Results Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 12.33% vs NA in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 53.23% vs NA in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 120.78% vs NA in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is 63.96% vs NA in Mar 2024
Compare Profit and Loss Results of Symbiotec Pharma
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
756.00
1,681.00
-925.00
-55.03%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
756.00
1,681.00
-925.00
-55.03%
Expenditure (Ex Depriciation)
Stock Adjustments
11.00
3.00
8.00
266.67%
Raw Materials Consumed
288.00
1,058.00
-770.00
-72.78%
Power & Fuel Cost
0.00
44.00
-44.00
-100.00%
Employee Cost
119.00
206.00
-87.00
-42.23%
Operating Expenses
50.00
62.00
-12.00
-19.35%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
2.00
90.00
-88.00
-97.78%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
17.00
31.00
-14.00
-45.16%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
537.00
1,569.00
-1,032.00
-65.77%
Operating Profit (PBDIT) excl Other Income
219.00
112.00
107.00
95.54%
Other Income
32.00
21.00
11.00
52.38%
Operating Profit (PBDIT)
251.00
133.00
118.00
88.72%
Interest
16.00
16.00
0.00
0.00%
Profit before Depriciation and Tax
234.00
117.00
117.00
100.00%
Depreciation
38.00
29.00
9.00
31.03%
Profit Before Taxation & Exceptional Items
196.00
88.00
108.00
122.73%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
196.00
89.00
107.00
120.22%
Provision for Tax
50.00
23.00
27.00
117.39%
Profit After Tax
145.00
66.00
79.00
119.70%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
589.00
429.00
160.00
37.30%
Profit Available for appropriations
734.00
495.00
239.00
48.28%
Appropriations
734.00
495.00
239.00
48.28%
Equity Dividend (%)
0%
10%
-10.00
Earnings Per Share
133.35
1.21
132.14
10,920.66%
Profit And Loss - Net Sales
Net Sales 756.68 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 12.33% vs NA in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 219.03 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 53.23% vs NA in Mar 2024
Profit And Loss - Interest
Interest 16.65 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 120.78% vs NA in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 145.83 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 63.96% vs NA in Mar 2024
